<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04127019</url>
  </required_header>
  <id_info>
    <org_study_id>MASTER</org_study_id>
    <nct_id>NCT04127019</nct_id>
  </id_info>
  <brief_title>Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)</brief_title>
  <official_title>Adjuvant Six Cycles of Docetaxel and Cyclophosphamide or Three Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by Three Cycles of Docetaxel Versus Four Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aimed to evaluate the noninferiority of a short-term anthracycline-free chemotherapy (TC,
      six cycles of docetaxel and cyclophosphamide) or a short-term anthracycline-based
      chemotherapy (CEF-T, three cycles of cyclophosphamide/epirubicin/fluorouracil followed by
      three cycles of docetaxel) to a standard anthracycline/taxane-containing chemotherapy (EC-P,
      epirubicin and cyclophosphamide for four cycles followed by paclitaxel for twelve weeks) in
      operable breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It was initiated as an adjuvant chemotherapy trial in 2010 to test noninferiority of an
      anthracycline-free short-term regimen (T75C600 x 6 [TC] once every 3 weeks) or a short-term
      regimen (C500E100F500 x 3 once every 3 weeks followed by T100 x 3 every 3 weeks [CEF-T])
      compared with a standard long-term anthracycline-containing regimen (E90C600 x 4 once every 3
      weeks followed by P80 x 12 once every week [EC-P]). Patients were randomly assigned (1:1:1)
      to each arm after completing surgical excision of primary tumor. Trastuzumab was administered
      in combination with chemotherapy to patients with HER2-positive breast cancer and sustained
      monotherapy as per the current guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2010</start_date>
  <completion_date type="Actual">June 15, 2017</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental: Arm 1 6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .
Experimental: Arm 2 3 cycles of FEC (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
Experimental: Arm 3 4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1+ , 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>distant disease-free survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2079</enrollment>
  <condition>Primary Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TC*6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CEF*3-T*3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EC*4-wP*12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel chemotherapy (injection)</description>
    <arm_group_label>EC*4-wP*12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel chemotherapy (injection)</description>
    <arm_group_label>CEF*3-T*3</arm_group_label>
    <arm_group_label>TC*6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide chemotherapy (injection)</description>
    <arm_group_label>CEF*3-T*3</arm_group_label>
    <arm_group_label>EC*4-wP*12</arm_group_label>
    <arm_group_label>TC*6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Epirubicin chemotherapy (injection)</description>
    <arm_group_label>CEF*3-T*3</arm_group_label>
    <arm_group_label>EC*4-wP*12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>5-fluorouracil chemotherapy (injection)</description>
    <arm_group_label>CEF*3-T*3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients, age at diagnosis 18 - 75 years

          -  Histological confirmed unilateral primary invasive carcinoma of the breast

          -  Adequate surgical treatment with complete resection of the tumor (R0) and resection of
             &gt; or = 10 axillary nodes or SLN in clinically N0 patients

          -  Node positive disease or node negative disease with at least one other risk factor
             (tumor size &gt; or = 2 cm, grade &gt; or = II)

          -  No evidence for distant metastasis (M0) after conventional staging

          -  Performance Status ECOG &lt; or = 1

          -  The patient must be accessible for treatment and follow-up

          -  LVEF&gt; 50%

          -  Negative pregnancy test (urine or serum) within 7 days prior to randomization in
             premenopausal patients

          -  Leucocytes &gt; or = 4 x 10^9/L

          -  platelets &gt; or = 100 x 10^9/L

          -  haemoglobin &gt; or = 9 g/dL

          -  total bilirubin &lt; or = 1.5 UNL

          -  ASAT (SGOT) and ALAT (SGPT) &lt; or = 2.5 UNL

          -  creatinine &lt; 175 mmol/L (2 mg/dL)

        Exclusion Criteria:

          1. Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy
             or endocrine therapyï¼‰;

          2. Has bilateral breast cancer;

          3. Has previous history of additional malignancy, with the exception of adequately
             treated basal cell carcinoma and cervical carcinoma in situ.

          4. Has metastic (Stage 4) breast cancer;

          5. Has any &gt;T4 lesion (UICC1987) (with skin involvement, mass adhesion and fixation, and
             inflammatory breast cancer);

          6. Is pregnant, is breast feeding women, or women of childbearing age who cannot practice
             effective contraceptives;

          7. Patients participating in other clinical trials at the same time;

          8. Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left
             ventricular ejection fraction (LVEF) &lt; 50% (cardiac ultrasound); severe cardio
             cerebral vascular disease within the 6 months previous of randomization (such as
             unstable angina, chronic heart failure, uncontrolled hypertension with blood
             pressure&gt;150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic
             patients with poor blood glucose control; patients with severe hypertension;

          9. Has known allergy to taxane and excipients;

         10. Has severe or uncontrolled infection.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Ming Shao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 12, 2019</study_first_submitted>
  <study_first_submitted_qc>October 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>February 23, 2020</last_update_submitted>
  <last_update_submitted_qc>February 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

